Abstract
We conducted a retrospective analysis of lenalidomide with dexamethasone for patients with relapsed/refractory multiple myeloma (RRMM) who were treated within the Korean patient access program. Lenalidomide has been approved for RRMM for several years in Europe and North America, but has not been accessible to Asian patients in the past. Between 2008 and 2012, 110 patients from 20 hospitals were enrolled. The overall response rate (ORR) was 43.6 % with 15.4 % of very good partial response (VGPR) or better. The median time to progression (TTP) in this heavily pretreated patient population was 8.0 months, and median overall survival (OS) was 23 months. Hematologic toxicities, fatigue, anorexia, and constipation were the most common adverse events. The number of previous treatment lines, previous exposure to thalidomide, refractoriness to thalidomide and bortezomib, pretreatment white blood cell count (WBC), platelet count, t(14;16), and 17p deletion were significant prognostic factors for TTP, and creatinine clearance, refractoriness to thalidomide and bortezomib, performance status, platelet count, and 17p deletion were significant for OS in univariate analysis. In multivariate analysis, WBC and platelet count were significant prognostic factors for TTP and performance status for OS. For Korean myeloma patients, lenalidomide showed considerable efficacy, and toxicities were comparable to the data published in Europe and North America.
| Original language | English |
|---|---|
| Pages (from-to) | 113-121 |
| Number of pages | 9 |
| Journal | Annals of Hematology |
| Volume | 93 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2014 Jan 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Hematology
Cite this
}
Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea - Experience from 110 patients. / Kim, Kihyun; Kim, Seok Jin; Voelter, Verena; Suh, Cheolwon; Yoon, Sung Soo; Lee, Je Jung; Kwak, Jae Yong; Ryoo, Hun Mo; Kim, Yang Soo; Moon, Joon Ho; Park, Seong Kyu; Kim, Sung Hyun; Mun, Yeung Chul; Kim, Jinseok; Eom, Hyeon Seok; Jo, Deog Yeon; Jun, Hyun Jung; Kim, Ki Hwan; Lee, Jeong Ok; Lee, Jae Hoon; Min, Chang Ki.
In: Annals of Hematology, Vol. 93, No. 1, 01.01.2014, p. 113-121.Research output: Contribution to journal › Article
TY - JOUR
T1 - Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea - Experience from 110 patients
AU - Kim, Kihyun
AU - Kim, Seok Jin
AU - Voelter, Verena
AU - Suh, Cheolwon
AU - Yoon, Sung Soo
AU - Lee, Je Jung
AU - Kwak, Jae Yong
AU - Ryoo, Hun Mo
AU - Kim, Yang Soo
AU - Moon, Joon Ho
AU - Park, Seong Kyu
AU - Kim, Sung Hyun
AU - Mun, Yeung Chul
AU - Kim, Jinseok
AU - Eom, Hyeon Seok
AU - Jo, Deog Yeon
AU - Jun, Hyun Jung
AU - Kim, Ki Hwan
AU - Lee, Jeong Ok
AU - Lee, Jae Hoon
AU - Min, Chang Ki
PY - 2014/1/1
Y1 - 2014/1/1
N2 - We conducted a retrospective analysis of lenalidomide with dexamethasone for patients with relapsed/refractory multiple myeloma (RRMM) who were treated within the Korean patient access program. Lenalidomide has been approved for RRMM for several years in Europe and North America, but has not been accessible to Asian patients in the past. Between 2008 and 2012, 110 patients from 20 hospitals were enrolled. The overall response rate (ORR) was 43.6 % with 15.4 % of very good partial response (VGPR) or better. The median time to progression (TTP) in this heavily pretreated patient population was 8.0 months, and median overall survival (OS) was 23 months. Hematologic toxicities, fatigue, anorexia, and constipation were the most common adverse events. The number of previous treatment lines, previous exposure to thalidomide, refractoriness to thalidomide and bortezomib, pretreatment white blood cell count (WBC), platelet count, t(14;16), and 17p deletion were significant prognostic factors for TTP, and creatinine clearance, refractoriness to thalidomide and bortezomib, performance status, platelet count, and 17p deletion were significant for OS in univariate analysis. In multivariate analysis, WBC and platelet count were significant prognostic factors for TTP and performance status for OS. For Korean myeloma patients, lenalidomide showed considerable efficacy, and toxicities were comparable to the data published in Europe and North America.
AB - We conducted a retrospective analysis of lenalidomide with dexamethasone for patients with relapsed/refractory multiple myeloma (RRMM) who were treated within the Korean patient access program. Lenalidomide has been approved for RRMM for several years in Europe and North America, but has not been accessible to Asian patients in the past. Between 2008 and 2012, 110 patients from 20 hospitals were enrolled. The overall response rate (ORR) was 43.6 % with 15.4 % of very good partial response (VGPR) or better. The median time to progression (TTP) in this heavily pretreated patient population was 8.0 months, and median overall survival (OS) was 23 months. Hematologic toxicities, fatigue, anorexia, and constipation were the most common adverse events. The number of previous treatment lines, previous exposure to thalidomide, refractoriness to thalidomide and bortezomib, pretreatment white blood cell count (WBC), platelet count, t(14;16), and 17p deletion were significant prognostic factors for TTP, and creatinine clearance, refractoriness to thalidomide and bortezomib, performance status, platelet count, and 17p deletion were significant for OS in univariate analysis. In multivariate analysis, WBC and platelet count were significant prognostic factors for TTP and performance status for OS. For Korean myeloma patients, lenalidomide showed considerable efficacy, and toxicities were comparable to the data published in Europe and North America.
UR - http://www.scopus.com/inward/record.url?scp=84891838863&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84891838863&partnerID=8YFLogxK
U2 - 10.1007/s00277-013-1893-z
DO - 10.1007/s00277-013-1893-z
M3 - Article
VL - 93
SP - 113
EP - 121
JO - Annals of Hematology
JF - Annals of Hematology
SN - 0939-5555
IS - 1
ER -